Showing results (111-120 of 122) with videos related to
Sort By:
Pageof 13
Hepatology (Baltimore, Md.)|January 19, 2022
Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attackYuan Fang, Weiren Liu, Zheng Tang, et al.Cell Discovery|January 17, 2023
A RIPK3-independent role of MLKL in suppressing parthanatos promotes immune evasion in hepatocellular carcinomaXifei Jiang, Wenjia Deng, Siyao Tao, et al.The Lancet. Oncology|September 1, 2025
Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 studyGuoming Shi, Xiaoyong Huang, Xiaowu Li, et al.Journal of Hepatology|March 16, 2022
Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesisRenqiang Sun, Zhiyong Zhang, Ruoxuan Bao, et al.Cell|December 28, 2020
Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinomaYunfan Sun, Liang Wu, Yu Zhong, et al.Cancer Cell|December 15, 2023
Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinomaYunfan Sun, Pin Wu, Zefan Zhang, et al.The Lancet. Gastroenterology & Hepatology|May 23, 2025
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trialYinghong Shi, Guohong Han, Jian Zhou, et al.Hepatobiliary Surgery and Nutrition|April 25, 2022
Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition)Hui-Chuan Sun, Jian Zhou, Zheng Wang, et al.Liver Cancer|January 14, 2021
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)Jian Zhou, Huichuan Sun, Zheng Wang, et al.Liver Cancer|October 30, 2023
Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)Jian Zhou, Huichuan Sun, Zheng Wang, et al.Pageof 13